T ension-type headache (TTH) is the most prevalent primary headache and the second most prevalent disorder in the world 1 . However, despite the great progress made in understanding the putative physiological and biological abnormalities of migraines in recent decades 2 , the same cannot be said for their counterpart, TTH, which has been relegated to the background by most investigators 3 and, now neglected 4 , can be considered the "ugly duckling" of headache disorders classified by the International Headache Society (IHS). In what is perhaps a vicious circle, few initiatives have been taken by independent academic or industry-financed researchers to change this situation.
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The physiological basis of TTH was explored in the 1990s 5 , and the findings allowed hypotheses for putative biochemical mechanisms associated with this type of headache to be drawn up 6 . Nevertheless, these hypothetical mechanisms have yet to be confirmed and, with few exceptions, the studies that have been carried out did not use animal models or test these mechanisms to the same level of detail as in migraine studies 2 . It is against this background that the paper in this edition by Domingues et al., who studied the role of neurotrophic factors in TTH down to the molecular level, acquires particular importance 7 . In a well-designed and carefully conducted cross-sectional study, Domingues et al. determined serum levels of brain-derived neurotrophic factor (BDNF), nerve-growth factor (NGF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) in forty-eight TTH patients and forty-eight age and gender-matched controls. The authors searched for a correlation between these neurotrophic factors and TTH (both episodic and chronic) as well as other measurable psychosocial variables 7 . Early studies of the pathophysiology of TTH supported the muscle-contraction theory, although TTH can occur with or without pericranial tenderness. The widespread acceptance this theory gained can be observed in a review by Maekawa et al. 8 , who discussed the factors supporting and refuting the putative role of adrenergic receptors and muscle hypoperfusion in myofascial pain.
Following a different line of investigation, and probably considering the similarities between migraine and TTH, such as their sharing of common triggers 3, 9 , Ashina et al. searched unsuccessfully for changes in neuropeptides such as substance P, neuropeptide Y and vasoactive intestinal polypeptide (VIP) in peripheral blood of patients with chronic tension-type headache (CTTH) 10, 11 . Their findings may have in fact been anticipated by Bach et al., who found normal levels of calcitonin gene-related peptide (CGRP) in the cerebrospinal fluid of patients with TTH 12, 13 . To date, the most consistent finding in the pathophysiology of CTTH has been the evidence that glyceryl-nitrate (GNT) infusion can induce late-onset tension-type-like headache in CTTH sufferers 14, 15 . These findings prompted a cross-over trial, which showed that NG-monomethyl-L-arginine hydrochloride (L-NMMA), an NOS inhibitor, decreases CTTH pain 16 . The authors hypothesized that NG-monomethyl-L-arginine hydrochloride (L-NMMA) may act on sensitized neurons. Neural sensitization in CTTH is far more than a hypothesis: there is plenty of indirect evidence for sensitization in CTTH, such as a slower recovery cycle of the R2 blink reflex in TTH 17 . On the other hand, the finding of a paradoxical facilitation of the R3 reflex response during the cold pressor test 17 pointed to an associated deficient descending inhibition 18 . To further complicate the puzzle, individuals with TTH were found to have increased pericranial muscle tenderness even in the absence of headache 17 . However, a study with 100 individuals found that CTTH subjects had normal pain thresholds prior to the development of CTTH but that these thresholds decreased in individuals who developed CTTH, suggesting that pain hypersensitivity is a consequence of frequent TTHs 19 . This sensitization is thought to be responsible for the pericranial tenderness 20 and hyperalgesia of neck and shoulder muscles in CTTH patients 21 . Nonetheless, the mechanism of central sensitization 22 is not completely understood and may depend on ''hyperalgesic priming'', a process that in turn depends on the epsilon isoform of protein kinase C (PKCe) and a switch in intracellular signaling pathways that mediate cytokine-induced nociceptor hyperexcitability 23 . In this scenario the relevance of neurotrophic factors, which are considered by some researchers to be essential for neuronal plasticity, becomes more evident, justifying the efforts of Domingues et al. 7 .
Neurotrophic Factors
The existence of neurotrophic factors was first posited in 1939 by Hamburger and The neurophysiology of nociception is based on the detection of noxious stimuli by nociceptors present in practically all organs. Nociceptors are small-diameter sensory neuron terminals (A fibers), most of which are polymodal and respond to noxious mechanical (pressure), thermal (heat and cold) and chemical stimuli 27 . Depolarization of these receptors causes voltage-gated sodium channels to open and, consequently, results in the generation of action potentials that propagate to the dorsal horn of the spinal cord. The release by nerve endings of substance P and a peptide genetically related to calcitonin in neurovascular junctions leads to vasodilation and plasma extravasation, causing neurogenic inflammation and nociceptor sensitization. The nociceptive threshold falls and fiber nociceptors respond more intensely to noxious stimuli than when they are not sensitized. Furthermore, the inflammatory process activates silent C fiber nociceptors and favors nociception secondary to mechanical or thermal stimuli (central sensitization), with abnormal characteristics of nociceptive pain, i.e., allodynia and hyperalgesia 28, 29 . This nociceptive activation promotes rapid structural changes and a longlasting increase in synaptic strength, resulting in hyperalgesia 29 . Studies have shown elevated intraneuronal NGF levels during inflammatory processes. These increased levels are associated with increased BDNF expression, which, although not contributing to the processing of nociceptive information in normal circumstances, contributes to inflammatory hypersensitivity 30 . It has been reported that the use of a receptor-inactivating protein (TrkA-IgG) to block the effects of endogenous NGF resulted in a reduction in sensitivity to thermal stimuli but no change in sensitivity to mechanical stimuli, showing that peripheral sensitivity can be regulated by NGFs 31 . Bennett (2001) notes that increased levels of NGF produce both short-term thermal hyperalgesia and mechanical and thermal hyperalgesia over time 29 . Studies in knockout rats suggest that NGF and TrkA are the mediators most closely associated with nociceptive pathways 33 (Table) . In addition, NGFs are not only important in the acute phase of the pain process but can also exert long-term effects on nociception by regulating B1 and B2 bradykinin, VR1 vanilloid and sodium channel receptors among others 34 . In short, neurotrophic factors are important modulators of the processing of nociceptive information in the peripheral and central nervous systems as they act on the pathophysiology of pain; NGF and BDNF antagonists are therefore potential therapeutic alternatives for pain management.
Readers can find further information about the findings of Domingues et al. 7 on the role of NF in TTH in their paper published in this issue. Whether their results confirm or reject their hypothesis, they remain consistent and will undoubtedly strengthen the wall of knowledge on TTH. 33 .
